All In Biotech

Drug Trial Radar · NCT02540993

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,734 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,734

Actual

Start

Sep 17, 2015

Primary completion

Apr 14, 2020

Study completion Apr 14, 2020

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.

Conditions

  • Chronic Kidney Disease

Interventions

  • Finerenone (BAY94-8862)Drug

    Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment

  • PlaceboDrug

    Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal DeathTime frame: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months

Locations

978 sites in 48 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Fort Payne, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Prescott, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Arvin, California

  • Site not named

    Chula Vista, California

  • Site not named

    Dublin, California

  • Site not named

    El Centro, California

  • Site not named

    Fresno, California

  • Site not named

    Fresno, California

  • Site not named

    La Mesa, California

  • Site not named

    Loma Linda, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Northridge, California

  • Site not named

    Port Hueneme, California

  • Site not named

    Poway, California

  • Site not named

    Rancho Cucamonga, California

  • Site not named

    Rialto, California

  • Site not named

    Roseville, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    Torrance, California

  • Site not named

    New Haven, Connecticut

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Fleming Island, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

Showing 40 of 978 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.